Summary
BeOne Medicines Ltd. (ONC) announced significant clinical trial data updates at the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program. The company presented follow-up data from the Phase 3 ASPEN trial comparing BRUKINSA™ (zanubrutinib) against ibrutinib for Waldenström’s macroglobulinemia (WM), along with long-term data in both treatment-naïve and relapsed/refractory WM patients. Furthermore, BeiGene showcased results from a Phase 3 trial evaluating its anti-PD-1 antibody, tislelizumab, in combination with chemotherapy for the first-line treatment of advanced squamous non-small cell lung cancer (NSCLC). These presentations at a major oncology conference underscore the company's ongoing progress in developing and validating its key drug candidates.
Key Highlights
- 1Presentation of updated head-to-head Phase 3 ASPEN trial results for BRUKINSA™ (zanubrutinib) versus ibrutinib in Waldenström’s macroglobulinemia (WM).
- 2Inclusion of long-term follow-up data from a Phase 1/2 study of zanubrutinib in both treatment-naïve and relapsed/refractory WM patients.
- 3Announcement of Phase 3 clinical trial results for tislelizumab (anti-PD-1 antibody) combined with chemotherapy in first-line advanced squamous non-small cell lung cancer (NSCLC).
- 4Data presented at the prestigious 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program.
- 5The company is actively advancing its late-stage clinical development pipeline for key oncology assets.
- 6These updates are crucial for demonstrating the efficacy and potential market positioning of zanubrutinib and tislelizumab.